EphA3/EFNA3 Reverse Signalling Promotes Epithelial-to-Mesenchymal Transition via ERK Pathway to Facilitate Colorectal...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Liver metastasis is a major cause of mortality in colorectal cancer (CRC).
• Understanding the molecular mechanisms driving CRC liver metastasis is crucial for developing effective therapies.
• Limited knowledge exists regarding specific molecular targets critical for CRC liver metastasis.

Purpose of the Study:

• To identify a potential therapeutic target for colorectal cancer (CRC) liver metastasis.
• To investigate the role of EphrinA3 (EFNA3) in CRC metastasis.
• To elucidate the molecular mechanisms underlying EFNA3-mediated CRC metastasis.

Main Methods:

• Analysis of Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases to identify EFNA3.
• Co-immunoprecipitation to investigate EFNA3 interacting proteins.
• In vitro and in vivo assays (transwell, wound healing, cell viability, tumor models) using EFNA3 knockdown and overexpressed CRC cells.
• Examination of the EphA3/EFNA3 axis and its downstream signaling pathways (ERK).

Main Results:

• EFNA3 expression is significantly elevated in CRC tissues, particularly in metastatic tissues, and correlates with advanced stages and poor outcomes.
• EFNA3 knockdown inhibits CRC cell migration, invasion, and proliferation in vitro and in vivo.
• EFNA3 overexpression enhances CRC cell migration, invasion, and proliferation.
• EphA3 binds to EFNA3, and EphA3/EFNA3 reverse signaling activates ERK1/2, promoting epithelial-to-mesenchymal transition (EMT) and metastasis.

Conclusions:

• EFNA3 plays a critical role in promoting colorectal cancer (CRC) liver metastasis.
• The EphA3/EFNA3 signaling axis promotes EMT by activating ERK signaling.
• The EphA3/EFNA3 axis represents a potential therapeutic target for metastatic CRC.